Literature DB >> 1421824

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.

G L Bray1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421824     DOI: 10.1016/s0887-7963(92)70176-x

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


× No keyword cloud information.
  2 in total

Review 1.  Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.

Authors:  G Bray
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

Review 2.  Blood safety and the choice of anti-hemophilic factor concentrate.

Authors:  Leonard A Valentino; Veeral M Oza
Journal:  Pediatr Blood Cancer       Date:  2006-09       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.